Mustang Bio Inc (NASDAQ: MBIO)’s stock price has gone rise by 15.38 in comparison to its previous close of 0.22, however, the company has experienced a 22.83% increase in its stock price over the last five trading days. globenewswire.com reported 2024-11-12 that WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced that by decision dated November 8, 2024, the Nasdaq Hearings Panel granted the Company’s request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $1.00 bid price requirement through January 31, 2025 and the $2.5 million stockholders’ equity requirement through February 18, 2025. The Company is considering all available options that may enable it to timely evidence compliance with the continued listing criteria and maintain its listing on Nasdaq; however, there can be no assurance that the Company will be able to do so.
Is It Worth Investing in Mustang Bio Inc (NASDAQ: MBIO) Right Now?
Moreover, the 36-month beta value for MBIO is 1.76. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MBIO is 41.79M and currently, short sellers hold a 0.85% of that float. On January 13, 2025, MBIO’s average trading volume was 8.15M shares.
MBIO’s Market Performance
MBIO stock saw an increase of 22.83% in the past week, with a monthly gain of 35.19% and a quarterly increase of 18.80%. The volatility ratio for the week is 18.52%, and the volatility levels for the last 30 days are 18.97% for Mustang Bio Inc (MBIO). The simple moving average for the last 20 days is 33.12% for MBIO’s stock, with a simple moving average of -19.18% for the last 200 days.
Analysts’ Opinion of MBIO
Many brokerage firms have already submitted their reports for MBIO stocks, with BTIG Research repeating the rating for MBIO by listing it as a “Buy.” The predicted price for MBIO in the upcoming period, according to BTIG Research is $11 based on the research report published on May 18, 2021 of the previous year 2021.
B. Riley FBR, on the other hand, stated in their research note that they expect to see MBIO reach a price target of $9. The rating they have provided for MBIO stocks is “Buy” according to the report published on October 02nd, 2020.
Cantor Fitzgerald gave a rating of “Overweight” to MBIO, setting the target price at $7 in the report published on November 20th of the previous year.
MBIO Trading at 20.64% from the 50-Day Moving Average
After a stumble in the market that brought MBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.23% of loss for the given period.
Volatility was left at 18.97%, however, over the last 30 days, the volatility rate increased by 18.52%, as shares surge +37.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.03% lower at present.
During the last 5 trading sessions, MBIO rose by +22.83%, which changed the moving average for the period of 200-days by -73.27% in comparison to the 20-day moving average, which settled at $0.1928. In addition, Mustang Bio Inc saw 44.97% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for MBIO
Current profitability levels for the company are sitting at:
- -8.36 for the present operating margin
- 0.53 for the gross margin
The net margin for Mustang Bio Inc stands at -8.12. The total capital return value is set at 3.07. Equity return is now at value -1191.31, with -168.70 for asset returns.
Based on Mustang Bio Inc (MBIO), the company’s capital structure generated -0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -37.71. The debt to equity ratio resting at -0.05. The interest coverage ratio of the stock is -6021.0.
Currently, EBITDA for the company is -48.06 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of 3.46. The receivables turnover for the company is 12.16for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.40.
Conclusion
To wrap up, the performance of Mustang Bio Inc (MBIO) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
